IMAGENEBIO INC (IMA) Stock Price & Overview
NASDAQ:IMA • US45175G2075
Current stock price
The current stock price of IMA is 5.75 USD. Today IMA is down by -1.37%. In the past month the price increased by 16.6%.
IMA Key Statistics
- Market Cap
- 61.238M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -7.21
- Dividend Yield
- N/A
IMA Stock Performance
IMA Stock Chart
IMA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IMA.
IMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMA. IMA has a great financial health rating, but its profitability evaluates not so good.
IMA Earnings
IMA Forecast & Estimates
7 analysts have analysed IMA and the average price target is 16.32 USD. This implies a price increase of 183.83% is expected in the next year compared to the current price of 5.75.
For the next year, analysts expect an EPS growth of 73.61% and a revenue growth -100% for IMA
IMA Groups
Sector & Classification
IMA Financial Highlights
Over the last trailing twelve months IMA reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS increased by 40.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.25% | ||
| ROE | -39.35% | ||
| Debt/Equity | 0 |
IMA Ownership
IMA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25 | 820.359B | ||
| JNJ | JOHNSON & JOHNSON | 17.96 | 542.756B | ||
| MRK | MERCK & CO. INC. | 21.61 | 272.255B | ||
| PFE | PFIZER INC | 8.86 | 152.391B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.2 | 117.972B | ||
| ZTS | ZOETIS INC | 16.49 | 49.567B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.59 | 28.645B | ||
| VTRS | VIATRIS INC | 5.94 | 17.245B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.07 | 11.031B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.586B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.117B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.111B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.91 | 4.916B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMA
Company Profile
ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Company Info
IPO: 2021-03-26
IMAGENEBIO INC
12526 High Bluff Drive
San Diego CALIFORNIA US
Employees: 15
Phone: 18573438292
IMAGENEBIO INC / IMA FAQ
Can you describe the business of IMAGENEBIO INC?
ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Can you provide the latest stock price for IMAGENEBIO INC?
The current stock price of IMA is 5.75 USD. The price decreased by -1.37% in the last trading session.
What is the dividend status of IMAGENEBIO INC?
IMA does not pay a dividend.
What is the ChartMill rating of IMAGENEBIO INC stock?
IMA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does IMAGENEBIO INC belong to?
IMAGENEBIO INC (IMA) operates in the Health Care sector and the Pharmaceuticals industry.
What is the employee count for IMA stock?
IMAGENEBIO INC (IMA) currently has 15 employees.
Can you provide the ownership details for IMA stock?
You can find the ownership structure of IMAGENEBIO INC (IMA) on the Ownership tab.